Nutlin-3b

Nutlin-3b, the inactive form of Nutlin-3 (HY-50696), is a p53/MDM2 inhibitor with an IC50 of 13.6 μM. Nutlin-3b is 150 times less potent in binding to MDM2 than Nutlin-3a (HY-10029) . Nutlin-3b is promising for research of cancers[1][2][3][4].

Product Specifications

CAS Number

[675576-97-3]

UNSPSC

12352005

Hazard Statement

H302, H319, H332, H372, H400

Target

E1/E2/E3 Enzyme; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Nutlin-3b.html

Purity

98.78

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1NCCN(C(N2[C@@H](C3=CC=C(Cl)C=C3)[C@@H](C4=CC=C(Cl)C=C4)N=C2C5=CC=C(OC)C=C5OC(C)C)=O)C1

Molecular Formula

C30H30Cl2N4O4

Molecular Weight

581.49

Precautions

H302, H319, H332, H372, H400

References & Citations

[1]Vassilev LT, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303 (5659) :844-8.|[2]Müller CR, et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007 Jul 1;121 (1) :199-205.|[3]Michaelis M, et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res. 2009 Jan 15;69 (2) :416-21. |[4]Zhang F, et al. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol. 2011 Jul 1;82 (1) :24-34.